Compounds / GH Axis / MK-677

MK-677

MK-677 (Ibutamoren — Oral GH Secretagogue, Non-Peptide)

GH AxisWell ResearchedFDA: Not approved; Phase II trials completedWADA: PROHIBITED — Category S2

Overview

Phase II clinical trials for GH deficiency, muscle wasting, hip fracture. Approved nowhere but extensively studied in humans. Oral bioavailability is major practical advantage.

Mechanism of Action

Non-peptide ghrelin receptor agonist. Orally bioavailable GH secretagogue. Long half-life (24h) enables once-daily oral dosing. Increases GH and IGF-1. Notable: increases appetite and may cause water retention and blood glucose elevation.

Molecular Profile

Molecular weight

624.8 Da (small molecule, orally active)

CAS number

159634-47-6

Key Research Findings

Oral bioavailability; 24h half-life; GH/IGF-1 elevation; appetite stimulation; bone density support.

Published Research

J Clin Endocrinol Metab (2008)

Nass R et al. Effects of MK-677 on GH pulsatility in the elderly

View source

Related GH Axis Compounds

Ipamorelin CJC-1295 (No DAC)CJC-1295 (DAC)Sermorelin Tesamorelin GHRP-2

Clinical Guidance

Research data is not a treatment plan. If you are considering MK-677, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.

Running MK-677? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator · Full deep dive · Peptide fundamentals